Loading clinical trials...
Loading clinical trials...
A Multicenter, Prospective, Post-marketing Evaluation of QLETLI (Adalimumab Injection) Treatment Clinical Study on Efficacy and Safety of Non-infectious Uveitis (UV)
Conditions
Interventions
QLETLI
Locations
7
China
Peking Union Medical College Hospital
Beijing, China
The Second Xiangya Hospital of Central South University
Changsha, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
The second hospital of Jilin University
Jilin, China
Tianjin Medical University Eye Hospital
Tianjin, China
Renmin Hospital of Wuhan University
Wuhan, China
Start Date
December 27, 2021
Primary Completion Date
December 30, 2024
Completion Date
December 30, 2024
Last Updated
December 24, 2024
NCT07218770
NCT05486468
NCT02706704
NCT06431373
NCT07262437
NCT07176130
Lead Sponsor
Bio-Thera Solutions
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions